Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

165.69 +4.40 (+2.73%)

Official Closing Price Updated: 7:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

October 14, 2025

From Glaukos Corporation

Via Business Wire

Expert Outlook: Glaukos Through The Eyes Of 7 Analysts ↗

October 13, 2025

Via Benzinga

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

October 08, 2025

From Glaukos Corporation

Via Business Wire

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

September 25, 2025

From Glaukos Corporation

Via Business Wire

Expert Outlook: Glaukos Through The Eyes Of 4 Analysts ↗

September 22, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Glaukos Announces Participation in Wells Fargo Healthcare Conference

August 13, 2025

From Glaukos Corporation

Via Business Wire

Glaukos (GKOS) Q2 Revenue Jumps 30% ↗

August 01, 2025

Via The Motley Fool

Glaukos Announces Second Quarter 2025 Financial Results

July 30, 2025

From Glaukos Corporation

Via Business Wire

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

July 09, 2025

From Glaukos Corporation

Via Business Wire

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗

February 24, 2025

Via Benzinga

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

June 25, 2025

From Glaukos Corporation

Via Business Wire

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

June 25, 2025

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in Upcoming Investor Conferences

May 13, 2025

From Glaukos Corporation

Via Business Wire

What 11 Analyst Ratings Have To Say About Glaukos ↗

May 02, 2025

Via Benzinga

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

May 01, 2025

Via Benzinga

Glaukos Announces First Quarter 2025 Financial Results

April 30, 2025

From Glaukos Corporation

Via Business Wire

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 23, 2025

From Glaukos Corporation

Via Business Wire

Forecasting The Future: 7 Analyst Projections For Glaukos ↗

April 16, 2025

Via Benzinga

Glaukos Announces the Release of its 2024 Sustainability Report

April 16, 2025

From Glaukos Corporation

Via Business Wire

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

April 09, 2025

From Glaukos Corporation

Via Business Wire

Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years ↗

March 28, 2025

Via Benzinga

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

March 11, 2025

From Glaukos Corporation

Via Business Wire

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery ↗

February 24, 2025

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.

Via Benzinga

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

February 24, 2025

From Glaukos Corporation

Via Business Wire

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday? ↗

February 21, 2025

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.

Via Benzinga

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition ↗

February 21, 2025

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

February 20, 2025

As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

February 20, 2025

From Glaukos Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.